Most of the breakthrough science in pharma continues to come from emerging biotechs, while the size, scale, expertise and connections of big pharma are still essential. How strategies are evolving in this situation was the subject of ‘Early-Stage Pharma Partnering – Building a Strategy For Success’, a big pharma panel at the LSX World Congress in London on 4 May.
Key Takeaway
Big pharma business development players discuss the ongoing global financial challenges and provide ‘how-to’ information for SMEs on making a strong pitch to secure a deal.
Biotechs are making more – and sometimes desperate – approaches to big pharma in the absence of alternatives. Some clinical...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
